Purple Biotech Ltd.
PPBT
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for thā¦ read more
Healthcare
Biotechnology
10 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.58
Price-0.63%
-$0.01
1Y
Price
Market Cap
$218.173k
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR-33.3%
3y CAGR-25.0%
5y CAGREarnings
-$26.166m
+0.8%
1y CAGR-12194.0%
3y CAGR-9120.6%
5y CAGREPS
-$9,933.94
+10.3%
1y CAGR-8294.0%
3y CAGR-6214.3%
5y CAGRBook Value
$9.664m
$14.417m
Assets$4.753m
Liabilities$184k
DebtDebt to Assets
1.3%
-
Debt to EBITDAFree Cash Flow
-$6.802m
-22.8%
1y CAGR+22.2%
3y CAGR+12.3%
5y CAGRNo items found.
Press Releases
Statements and updates from the company